SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

Mail Stop 6010

	March 1, 2006

Paul W. Sandman, Esq.
Executive Vice President, Secretary and General Counsel
Boston Scientific Corporation
One Boston Scientific Plaza
Natick, Massachusetts 01760-1537

Re:	Boston Scientific Corporation
	Joint Proxy Statement/Prospectus on Form S-4
      Filed February 6, 2006
	File No. 333-131608

Dear Mr. Sandman:

      We have reviewed your letter submitted on February 28, 2006
and
the related changed pages and have the following comments.  Where
indicated, we think you should revise your document in response to
these comments.  If you disagree, we will consider your
explanation
as to why our comment is inapplicable or a revision is
unnecessary.
Please be as detailed as necessary in your explanation.  In some
of
our comments, we may ask you to provide us with information so we
may
better understand your disclosure.  After reviewing this
information,
we may raise additional comments.

      Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects.  We welcome
any questions you may have about our comments or any other aspect
of
our review.  Feel free to call us at the telephone numbers listed
at
the end of this letter.

1. We note the revisions you have made in response to our prior
comment 2.  After the first occurrence of your disclosure of the
trading price of Boston Scientific`s and Guidant`s common stock as
of
January 24, 2006 and as of a recent practical date, please clearly
compare that information with the implied aggregate merger
consideration per share of Guidant`s common stock.

2. We note from your revised disclosure on page 95 that of the $14
billion available pursuant to the commitment letter, you will only
be
using approximately $7.1 billion to finance the cash portion of
the
merger consideration.  Please revise your disclosure to clarify
why
you have secured a commitment in excess of the amount you intend
to
use to fund the cash portion of the merger consideration.  Also,
please disclose the fees that Boston Scientific will incur as a
result of obtaining the financing arrangements contemplated in the
commitment letter.

3. Please disclose, if true, that the amount available under the
revolving facility will be reduced by the amount of the proceeds
you
receive from the sale of your securities to Abbott.

* * *

      As appropriate, please amend your registration statement in
response to these comments.  You may wish to provide us with
marked
copies of the amendment to expedite our review.  Please furnish a
cover letter with your amendment that keys your responses to our
comments and provides any requested information.  Detailed cover
letters greatly facilitate our review.  Please understand that we
may
have additional comments after reviewing your amendment and
responses
to our comments.

      We direct your attention to Rules 460 and 461 regarding
requesting acceleration of a registration statement.  Please allow
adequate time after the filing of any amendment for further review
before submitting a request for acceleration.  Please provide this
request at least two business days in advance of the requested
effective date.

      Please contact Tim Buchmiller at (202) 551-3635 or me at
(202)
551-3444 with any questions regarding our comments.

      Sincerely,

      Perry Hindin
      Special Counsel

cc:	Peter D. Lyons, Esq. (via fax)
	Clare O`Brien, Esq. (via fax)
	Scott D. Petepiece, Esq. (via fax)

??

??

??

??

Paul W. Sandman, Esq.
Boston Scientific Corporation
March 1, 2006
Page 1

</TEXT>
</DOCUMENT>